Current advances in research and clinical applications of PLGA-based nanotechnology

Expert Rev Mol Diagn. 2009 May;9(4):325-41. doi: 10.1586/erm.09.15.


Co-polymer poly(lactic-co-glycolic acid) (PLGA) nanotechnology has been developed for many years and has been approved by the US FDA for the use of drug delivery, diagnostics and other applications of clinical and basic science research, including cardiovascular disease, cancer, vaccine and tissue engineering. This article presents the more recent successes of applying PLGA-based nanotechnologies and tools in these medicine-related applications. It focuses on the possible mechanisms, diagnosis and treatment effects of PLGA preparations and devices. This updated information will benefit to both new and established research scientists and clinical physicians who are interested in the development and application of PLGA nanotechnology as new therapeutic and diagnostic strategies for many diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Absorbable Implants
  • Animals
  • Biocompatible Materials
  • Drug Delivery Systems*
  • Humans
  • Lactic Acid* / chemistry
  • Materials Testing
  • Nanoparticles
  • Nanotechnology / methods
  • Polyglycolic Acid* / chemistry
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Tissue Engineering / methods


  • Biocompatible Materials
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid